Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Enbrel · 3 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| Enbrel (etanercept) | DRUG | - |
Inclusion Criteria: 1. Must be of Chinese ancestry and living in China. 2. Diagnosis of AS, as defined by Modified New York Criteria for Ankylosing Spondylitis. 3. Active AS at time of enrollment, defined by average of visual analog scale (VAS) values for duration and intensity of morning stiffness...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 1 | PHASE2 | Tulisokibart |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY002-072 |
| XBiotech, Inc. | XBIT | 1 | PHASE2 | vilamakitug |
| Sunshine Biopharma Incorporated | SBFM | 2 | PHASE3 | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | - | Upadacitinib |
| Novartis AG Sponsored ADR | NVS | 1 | - | Secukinumab |
| Pfizer Inc. | PFE | 1 | - | Tofacitinib |
| TScan Therapeutics, Inc. | TCRX | 1 | - | Undisclosed |
Enbrel is used for the treatment of ankylosing spondylitis and psoriasis. It is also studied in healthy subjects for pharmacokinetic evaluation. The drug is in Phase 3 clinical development for these indications, with completed trials in ankylosing spondylitis and psoriasis.
Enbrel is developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE. The company is conducting clinical trials to evaluate the drug's efficacy and safety in patients with ankylosing spondylitis and psoriasis.
Enbrel is in Phase 3 clinical development. Clinical trials have been completed for ankylosing spondylitis and psoriasis, with a total of 421 participants enrolled across studies. The drug is investigational and not yet approved for these indications.
Enbrel has completed Phase 3 trials including NCT00421915 and NCT00434044 for ankylosing spondylitis, and NCT00482170 for psoriasis. A Phase 1 trial, NCT00502879, studied the drug in healthy Chinese male subjects. All trials are completed.
Yes, Enbrel is the same as etanercept. Clinical trial titles refer to etanercept as the active substance. The drug is being studied for ankylosing spondylitis and psoriasis, with completed Phase 3 trials.